INMHealthcare · Drug Manufacturers - Specialty & GenericINM Stock Forecast: InMed Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile.
INM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores InMed Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Volatility (4): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own InMed Pharmaceuticals, Inc. — and when they’d sell — is the membership.
INM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Dec 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 29 Nov 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Feb 2021 | Roth Capital | Maintains | Buy | $12 → $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
INM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
InMed Pharmaceuticals, Inc. (INM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 1.6×
- Price / book
- 0.7×
- EV / EBITDA
- −0.0×
Cheaper than 74% of US stocks
Cheaper than 59% of US stocks
Cheaper than 80% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −162.8%
- Net margin
- −172.2%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 12% of US stocks
Higher than 3% of US stocks
- Return on equity
- −112.6%
- Return on assets
- −54.6%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
INM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INM appears on the weeks it earns a place.
Frequently asked questions about INM stock
How does Ticker Nerd's model rank INM?
As at 1 Aug 2026, InMed Pharmaceuticals, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the INM stock forecast for 2030?
No analyst covering InMed Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INM are extrapolating price history, which says nothing about the business.
How has INM stock performed over the past year?
InMed Pharmaceuticals, Inc. returned -38.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does InMed Pharmaceuticals, Inc. do?
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based medicines and related manufacturing technologies.
About InMed Pharmaceuticals, Inc.
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based medicines and related manufacturing technologies. InMed Pharmaceuticals Inc. operates through two main segments: InMed Pharma, which researches and develops small molecule drug candidates targeting CB1 and CB2 receptors, and BayMedica Commercial, which produces and commercializes rare cannabinoids for use as ingredients in the health and wellness industry. Its current pipeline includes therapeutic programs for areas such as Alzheimer’s disease, ocular conditions, and dermatological disorders, reflecting a concentration on diseases with significant unmet medical need. The company also develops biosynthesis-based processes for pharmaceutical-grade cannabinoid production, supporting both drug development and ingredient supply. Headquartered in Vancouver, Canada, InMed Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market at the intersection of cannabinoid science, drug discovery, and advanced manufacturing.
CEO Mr. Eric A. Adams B.S. Chem., M.I.B. · 13 employees · Canada · https://www.inmedpharma.com